{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T11:55:02Z","timestamp":1791374102932,"version":"4.3.1"},"reference-count":9,"publisher":"Galenos Yayinevi","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mirt"],"DOI":"10.4274\/mirt.galenos.2026.18863","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:31:24Z","timestamp":1791289884000},"source":"Crossref","is-referenced-by-count":0,"title":["Combined Maximum Tolerated Activity and Lesion-based Dosimetry for Personalized Radioiodine Therapy in Metastatic Differentiated Thyroid Carcinoma: An Early Institutional Experience"],"prefix":"10.4274","author":[{"given":"Nadiah Abd","family":"Razak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hwee Meng Joanne","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeline","family":"Mathew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siti Zarina Amir","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haizana","family":"Hairuman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2811","published-online":{"date-parts":[[2026,10,6]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Sta-tistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209-249.","DOI":"10.3322\/caac.21660"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1177\/10507256251363120","article-title":"2025 American Thyroid Association Management Guidelines for adult patients with differentiated thyroid cancer","volume":"35","author":"Ringel","year":"2025","unstructured":"2. Ringel MD, Sosa JA, Baloch Z, Bischoff L, Bloom G, Brent GA, Brock PL, Chou R, Flavell RR, Goldner W, Grubbs EG, Haymart M, Larson SM, Leung AM, Osborne JR, Ridge JA, Robinson B, Steward DL, Tufano RP, Wirth LJ. 2025 American Thyroid Association Management Guidelines for adult patients with differentiated thyroid cancer. Thyroid. 2025;35:841-985.","journal-title":"Thyroid"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1007\/s00259-008-0761-x","article-title":"EANM Dosimetry Commit-tee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy","volume":"35","author":"Lassmann","year":"2008","unstructured":"3. Lassmann M, H\u00e4nscheid H, Chiesa C, Hindorf C, Flux G, Luster M. EANM Dosimetry Commit-tee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy. Eur J Nucl Med Mol Imaging. 2008;35:1405-1412.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4. Nagarajah J, Janssen M, Hetkamp P, Jentzen W. Iodine symporter targeting with 124I\/131I Theranostics. J Nucl Med. 2017;58(Suppl 2):34S-38S.","DOI":"10.2967\/jnumed.116.186866"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.2967\/jnumed.107.047159","article-title":"Optimized 124I PET dosimetry protocol for radioiodine therapy of differentiated thyroid cancer","volume":"49","author":"Jentzen","year":"2008","unstructured":"5. Jentzen W, Freudenberg LS, Eising EG, Sonnenschein W, Knust J, Bockisch A. Optimized 124I PET dosimetry protocol for radioiodine therapy of differentiated thyroid cancer. J Nucl Med. 2008;49:1017-1023.","journal-title":"J Nucl Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1089\/thy.2014.0616","article-title":"Validation of a simple thyroid cancer dosimetry model based on the fractional whole-body retention at 48 hours post-administration of 131I","volume":"25","author":"Atkins","year":"2015","unstructured":"6. Atkins F, Van Nostrand D, Moreau S, Burman K, Wartofsky L. Validation of a simple thyroid cancer dosimetry model based on the fractional whole-body retention at 48 hours post-administration of 131I. Thyroid. 2015;25:1347-1350.","journal-title":"Thyroid"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1200\/JCO.21.01841","article-title":"Association between radioactive iodine treatment for pediatric and young adulthood differenti-ated thyroid cancer and risk of second primary malignancies","volume":"40","author":"Pasqual","year":"2022","unstructured":"7. Pasqual E, Schonfeld S, Morton LM, Villoing D, Lee C, Berrington de Gonzalez A, Kitahara CM. Association between radioactive iodine treatment for pediatric and young adulthood differenti-ated thyroid cancer and risk of second primary malignancies. J Clin Oncol. 2022;40:1439-1449.","journal-title":"J Clin Oncol"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8. Kuker R, Sztejnberg M, Gulec S. I-124 Imaging and dosimetry. Mol Imaging Radionucl Ther. 2017;26(Suppl 1):66-73.","DOI":"10.4274\/2017.26.suppl.07"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1007\/s00259-002-0945-8","article-title":"The clinical effects of thyroid stun-ning after diagnostic whole-body scanning with 185 MBq 131I","volume":"29","author":"Lees","year":"2002","unstructured":"9. Lees W, Mansberg R, Roberts J, Towson J, Chua E, Turtle J. The clinical effects of thyroid stun-ning after diagnostic whole-body scanning with 185 MBq 131I. Eur J Nucl Med Mol Imaging. 2002;29:1421-1427.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Molecular Imaging and Radionuclide Therapy"],"original-title":[],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T11:24:28Z","timestamp":1791372268000},"score":1,"resource":{"primary":{"URL":"https:\/\/mirt.tsnmjournals.org\/articles\/combined-maximum-tolerated-activity-and-lesion-based-dosimetry-for-personalized-radioiodine-therapy-in-metastatic-differentiated-thyroid-carcinoma-an-early-institutional-experience\/doi\/mirt.galenos.2026.18863"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,6]]},"references-count":9,"URL":"https:\/\/doi.org\/10.4274\/mirt.galenos.2026.18863","relation":{},"ISSN":["2146-1414","2147-1959"],"issn-type":[{"value":"2146-1414","type":"print"},{"value":"2147-1959","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,6]]}}}